Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.

ABSTRACT: The nonsteroidal mineralocorticoid receptor (MR) blocker esaxerenone has demonstrated good antihypertensive activity in a variety of patients, including those with uncomplicated grade I-III hypertension, hypertension with moderate renal dysfunction, hypertension with type 2 diabetes mellitus with albuminuria, and hypertension associated with primary aldosteronism. Hyperkalemia has long been recognized as a potential side effect occurring during treatment with MR blockers, but there is a lack of understanding and guidance about the appropriate management of hyperkalemia during antihypertensive therapy with MR blockers, especially in regard to the newer agent esaxerenone. In this article, we first highlight risk factors for hyperkalemia, including advanced chronic kidney disease, diabetes me

SUBMITTER: Rakugi H 

PROVIDER: S-EPMC8019656 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature